Successful Treatment of Concurrently Diagnosed Multiple Myeloma and Myelodysplastic Syndrome With Isolated Del(5q) With Lenalidomide, Bortezomib, and Dexamethasone

Lenalidomide is known to be an effective therapy for multiple myeloma and for myelodysplastic syndrome (MDS) with isolated del(5q). We report the case of a patient simultaneously diagnosed with multiple myeloma and myelodysplastic syndrome with isolated del(5q) who was treated successfully with lenalidomide, bortezomib, and dexamethasone. The treatment achieved a stringent complete response of multiple myeloma and a hematologic and cytogenetic response of MDS in three months. Our experience suggests that standard myeloma induction regimens including lenalidomide and a proteasome inhibitor may be considered for treatment of concurrently diagnosed multiple myeloma and MDS with isolated del(5q) and are safe to use in select patients.

Automated summary

Lenalidomide is effective in treating both multiple myeloma and myelodysplastic syndrome with isolated del(5q), as shown in a case report where a patient with both conditions achieved a complete response with lenalidomide, bortezomib, and dexamethasone treatment within three months. This suggests that standard induction regimens containing lenalidomide and a proteasome inhibitor may be safe and effective for patients with concurrent diagnoses of multiple myeloma and MDS with isolated del(5q).